Evaluation of the HeartLogic Diagnostic in Optimizing Guideline-directed Medical Therapy in Patients With Congestive Heart Failure and Chronically Low Ejection Fractions (EFs)

A trial with no phase registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 135 participants.

Also called NCT07412626

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose supportive care
Phase
Not applicable
Enrolled
  • 135 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07412626
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07412626. Randomized; no masking; primary purpose supportive care. Start 2026-04-01 (anticipated); primary completion 2027-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Evaluation of the HeartLogic Diagnostic in Optimizing Guideline-directed Medical Therapy in Patients With Congestive Heart Failure and Chronically Low Ejection Fractions (EFs)
Acronym
Heartlogic ISR
Condition
Congestive Heart Failure Chronic
Condition
Low Ejection Fraction
Intervention (Device)
Heartlogic Diagnostic Tool Threshold Change
Intervention (Device)
Heartlogic Diagnostic Tool Unchanged Threshold
Lead sponsor
Robert Pickett (class: industry)
Collaborator
Boston Scientific Corporation (class: industry)
Collaborator
Ascension Health (class: industry)

Record details

Record id
cardio:ct-nct07412626
Content hash
db7468263d17a8757c1d110354dac11978565a8f98579fad8b3c7feea96779b0